<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823927</url>
  </required_header>
  <id_info>
    <org_study_id>2005H0197</org_study_id>
    <secondary_id>2005H0197</secondary_id>
    <nct_id>NCT00823927</nct_id>
  </id_info>
  <brief_title>Alveolar Macrophage Proteomics in HIV-associated Emphysema</brief_title>
  <acronym>HIVE</acronym>
  <official_title>Alveolar Macrophage Proteomics in HIV-associated Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Diaz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to examine lung function changes in individuals with HIV infection&#xD;
      and to understand why individuals with HIV have increased risk of lung damage from cigarette&#xD;
      smoking.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To delineate the natural history of HIV associated emphysema in the HAART era. To compare the&#xD;
      alveolar macrophage proteomes from HIV-seropositive smokers with emphysema to the alveolar&#xD;
      macrophages proteomes of both HIV+ smokers without emphysema and HIV- smokers.&#xD;
&#xD;
      To establish whether coinfection with HIV and Hepatitis C results in accelerated lung disease&#xD;
      manifested by decrements in forced expiratory volume and carbon monoxide diffusing capacity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 21, 2006</start_date>
  <completion_date type="Actual">June 23, 2008</completion_date>
  <primary_completion_date type="Actual">June 23, 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>examine the natural history of smoking related lung damage in patients with HIV</measure>
    <time_frame>3 years</time_frame>
    <description>HIV-Seropositive individuals are at increased risk of developing pulmonary emphysema (1,2). With improved therapy for HIV, and increased life expectancy in this population with a high smoking prevalence, chronic obstructive pulmonary disease (COPD) may assume an increasingly important role with respect to health related quality of life and medical complications. This research will provide a unique opportunity to examine the natural history of smoking related lung damage in patients with HIV infection. In addition, this research will involve sampling of lung cells to determine if there are unique proteins present that may be related to the increased risk of emphysema in this population. This may shed important insight into how the lung responds to injury and how it repairs itself. If critical proteins can be identified, treatment strategies may eventually be developed to either decrease proteins causing injury or increase protective proteins.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">365</enrollment>
  <condition>HIV</condition>
  <condition>Emphysema</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Alveolar macrophage proteomes from HIV-seropositive smokers with emphysema</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Alveolar macrophages proteomes of both HIV+ smokers without emphysema and HIV- smokers.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood lung fluid (optional)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        community sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically stable HIV-seropositive (and HIV-seronegative) individuals&#xD;
&#xD;
          -  Ages 18 years and older&#xD;
&#xD;
          -  Female subjects on no oral contraception with a negative pregnancy test&#xD;
&#xD;
          -  Subjects capable of giving written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known medical illness that would preclude bronchoscopy/BAL (e.g. unstable angina, new&#xD;
             cardiac arrhythmia). This only pertains to subjects involved in the bronchoscopy phase&#xD;
             of the study.&#xD;
&#xD;
          -  Pregnant females&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip T Diaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Philip Diaz</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>lung damage</keyword>
  <keyword>cigarette smoking</keyword>
  <keyword>HIV-seropositive</keyword>
  <keyword>emphysema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

